AAMU
VIR icon

Amundi Asset Management US’s Vir Biotechnology VIR Stock Holding History

Amundi Asset Management US’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$332K Sell
6,475
-10,536
-62% -$568K ﹤0.01% 1393
2020
Q4 		$456K Buy
17,011
+5,811
+52% +$189K ﹤0.01% 1310
2020
Q3 		$384K Hold
11,200
– – ﹤0.01% 1292
2020
Q2 		$459K Hold
11,200
– – ﹤0.01% 1262
2020
Q1 		$384K Buy
+11,200
New +$301K ﹤0.01% 1244

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.44B AUM 23.16% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Amundi Asset Management US's VIR Position: Q1 2021 in Review

Amundi Asset Management US reduced its Vir Biotechnology (VIR) stake by 62% in Q1 2021, selling an estimated $568K and leaving 6,475 shares worth $332K. The position accounts for ﹤0.01% of the portfolio, ranked #1393.

Amundi Asset Management US first reported a position in VIR in Q1 2020 and has held it in 5 quarters since. The position peaked at $459K in Q2 2020. 157 funds tracked by Wall St. Rank hold VIR as of Q1 2021.

  • Amundi Asset Management US held 6,475 shares of Vir Biotechnology worth $332K as of Q1 2021.
  • Amundi Asset Management US sold 10,536 Vir Biotechnology shares in Q1 2021, an estimated $568K.
  • Vir Biotechnology made up ﹤0.01% of Amundi Asset Management US's portfolio in Q1 2021, its #1393 holding.
  • Amundi Asset Management US first reported a position in Vir Biotechnology in Q1 2020 and has held it in 5 quarters since.
  • Amundi Asset Management US's Vir Biotechnology position peaked at $459K in Q2 2020.
  • 157 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.